Defined as scarce expression of hormone receptors and human epidermal growth factor receptor 2, triple-negative breast cancer (TNBC) is labeled as the most heterogeneous subtype of breast cancer with poorest prognosis. Despite rapid advancements in precise subtyping and tailored therapeutics, the ensuing cancer therapy-related cardiovascular toxicity (CTR-CVT) could exert detrimental impacts to TNBC survivors. Nowadays, this interdisciplinary issue is incrementally concerned by cardiologists, oncologists and other pertinent experts, propelling cardio-oncology as a booming field focusing on the whole-course management of cancer patients with potential cardiovascular threats. Here in this review, we initially profile the evolving molecular subtyping and therapeutic landscape of TNBC. Further, we introduce various monitoring approaches of CTR-CVT. In the main body, we elaborate on typical cardiotoxicities ensuing anti-TNBC treatments in detail, ranging from chemotherapy (especially anthracyclines), surgery, anesthetics, radiotherapy to immunotherapy, with future perspectives on promising directions in the era of artificial intelligence and traditional Chinese medicine.
Keyphrases
- artificial intelligence
- epidermal growth factor receptor
- cancer therapy
- machine learning
- tyrosine kinase
- big data
- deep learning
- advanced non small cell lung cancer
- locally advanced
- small molecule
- endothelial cells
- poor prognosis
- early stage
- minimally invasive
- drug delivery
- palliative care
- coronary artery bypass
- radiation therapy
- young adults
- oxidative stress
- radiation induced
- induced pluripotent stem cells
- advanced cancer
- percutaneous coronary intervention
- acute coronary syndrome
- childhood cancer
- computed tomography
- climate change
- squamous cell
- long non coding rna
- quantum dots
- surgical site infection
- atrial fibrillation
- loop mediated isothermal amplification
- sensitive detection
- binding protein